Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | CCKAR | P32238 | 2/20 | 0.44 |
| ▸ | RPA1 | P27694 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.42 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.42 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.41 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.41 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13157968 | 0.93 | RPA1 (0.53) | PTGS2FAAHCCKARRPA1MGLL | |
| SCHEMBL13158120 | 0.92 | RPA1 (0.45) | PTGS2CCKARRPA1MGLLKCNJ6 | |
| SCHEMBL13157726 | 0.92 | PTGS2 (0.48) | PTGS2RPA1MGLLALOX5PTGS1 | |
| SCHEMBL13158111 | 0.91 | FAAH (0.47) | PTGS2FAAHCCKARRPA1CA1 | |
| SCHEMBL13157981 | 0.89 | KCNJ6 (0.49) | PTGS2FAAHCCKARRPA1MGLL | |
| SCHEMBL13157986 | 0.88 | CCKAR (0.48) | CCKAR | |
| SCHEMBL13157959 | 0.88 | CCKAR (0.48) | CCKAR | |
| SCHEMBL13157976 | 0.87 | PTGS2 (0.55) | PTGS2CCKARALOX5PTGS1 | |
| SCHEMBL13157991 | 0.87 | PTGS2 (0.55) | PTGS2CCKARALOX5PTGS1 | |
| SCHEMBL13158107 | 0.85 | KCNJ6 (0.43) | PTGS2CCKARRPA1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | UROD, UTS2R, SLC14A1 | PTGS2 567/4885FAAH 1533/4885CCKAR 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.